Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07428746 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

Study acronym: GLOW
StatusRecruiting
PhasePhase 3
Started2026-05-07
View on ClinicalTrials.gov ↗

Amendment history

2026-07-30
Study Status, Eligibility, Contacts/Locations v1
Recruitment opened
Start dateestimated 2026-04→confirmed 2026-05-07
Eligibility criteria-29 characters
[...] x (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive) Hemoglobin A1c between >7-10% within 3 months of the first visit. Willingness and abilit [...] creening: treated with GLP-1RA, GIP analogues, pioglitazones or DPP-4 inhibitors Concomitant treatment with GLP-1 receptor agonist therapy Long-term intravenous, oral, and intra-articular administration of high-dose corticosteroids within 2 months before screening (more [...]
Study sitesdetails revised at 1 of 1 site
2026-02-17
Original filing
Emory University
371 trials monitored
See 23 trials at risk
Diabetes
4,247 trials monitored
See 176 trials at risk
Type 2 Diabetes
2,082 trials monitored
See 101 trials at risk
The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing
Trial Details
NCT Number NCT07428746
Lead Sponsor Emory University
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions Diabetes Mellitus, Type 2
Enrollment 20 participants
Start Date 2026-05-07
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-03